Vitro Diagnostics (OTCMKTS:VODG - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are b

California Public Employees Retirement System raised its position in Biogen Inc. (NASDAQ: BIIB) by 3

Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to a

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the a

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026

Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's diseas

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly

Stocks are cautiously higher midday, as cooler inflation helps investors forget about higher oil pri

LEQEMBIÂ Real-World LEADER Study Presented at AAICÂ 2026 Finds Over 75% of Early Alzheimer's Patient

Biogen Inc. (NASDAQ:BIIB) on Tuesday said it will advance investigational Alzheimer's therapy dirane

Biogen stock drops 9% as Phase 2 diranersen data raises analyst questions, despite Phase 3 plans and

Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that results from the real-world Lecan

Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Impo

The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a

Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen,

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that i

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data

TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDA

LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for i

The U.S. FDA on Monday approved an ​at-home starting dose of Eisai's and Biogen's Alzheimer's drug,

Energy names help cushion the Dow as oil jumps on U.S.-Iran tensions and investors brace for key ear

Biogen stock receives a bullish upgrade based on expectations the market will cheer the company's de

Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AX

Truist Securities analyst Srikripa Devarakonda upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lo

A July filing shows that Representative Maria Elvira Salazar reported a purchase in Brookfield Renew

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises th

Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will

Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key p

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clin

Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target f

Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax t

Congresswoman Maria Elvira Salazar is buying stocks once again in 2026. Here's the new stocks sh

Top Wall Street analysts upgraded Biogen Inc. and Cognizant Technology Solutions, see analyst rating

The Nasdaq Composite surged 15.3% in April, marking its strongest monthly gain since the early pande

Top analysts changed outlook on top names, including upgrades, downgrades & initiations. Check a

U.S. stocks bounce sharply on Tuesday as lower Treasury yields and Trump's signals of a potentia

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and

As a result of the reconstitution, the following six companies will be removed from the Index: Bioge

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.